Financial disclosures
|
|
- Everett Golden
- 5 years ago
- Views:
Transcription
1 Financial disclosures Named co-inventor on PCT applications CH2012/ and PCT2014/CH Chief Scientific Officer EMAGine SA
2 Historical decision in Future: extremely thin corneas Dresden ( 3 mw/cm 2 for 30 min) = 330 µm effect Recommendation: only treat if 400 µm 300 µ Wollensak et al., 1998 Seiler & Hafezi, 2006
3 Treat thin corneas 1. Future: extremely thin corneas JCRS, 2009
4 Other techniques 1. Future: extremely thin corneas Hypoosmolar CXL Contact-lens-assisted Transepithelial CXL Epithelial island CXL
5 Modify depth of effect 1. Future: extremely thin corneas Modify Modify Riboflavin Modify UV Thickness concentration intensity Hypoosmolar CXL Transepithelial CXL Contact-lens-assisted Epithelial island CXL
6 New model 1. Future: extremely thin corneas Modify UV intensity Riboflavin diffusion kinetics Oxygen diffusion kinetics
7 Fixed fluence (5.4 J/cm 2 ) 1. Future: extremely thin corneas 400 µm 300 µm
8 Fixed fluence (5.4 J/cm 2 ) 1. Future: extremely thin corneas 400 µm 300 µm Hypoosmolar Contact lens-assisted
9 Adapted fluence 1. Future: extremely thin corneas 400 µm 300 µm 250 µm 3 mw/cm 2 for 30 3 mw/cm 2 for xx 3 mw/cm 2 for xx 5.4 J/cm 2 xx J/cm 2 xx J/cm 2
10 New model to adapt CXL effect between 1. Future: extremely thin corneas Kling & Hafezi., JRS, in press
11 Treat corneas thinner between 200 and 400 µm 1. Future: extremely thin corneas Currently 32 eyes Depth of demarcation line at 1 month Treated so far: 270 µm to 395 µm
12 Simplified protocol 1. Future: extremely thin corneas 1. Perform abrasio 2. Instill riboflavin with speculum in place 3. Measure thickness after hypoosmolar riboflavin installation 4. Adapt the total fluence and treat
13 Conclusions 1. Future: extremely thin corneas The future: customized settings for every corneal thickness Use one single riboflavin solution: no more confusion with multiple different riboflavin solutions Can the CXL effect stabilize a 250 µm cornea?
14 AMR (Antimicrobial resistance), a global problem
15 AMR, a global problem ANTIMICROBIAL RESISTANCE Global Report on surveillance 2014 What you need to know WHO s first global report on antimicrobial resistance, with a focus on antibiotic resistance, reveals that it is no longer a prediction for the future. Antibiotic resistance - when bacteria change and antibiotics fail - is happening right now, across the world The report is the most comprehensive picture to date, with data provided by 114 countries Looking at 7 common bacteria that cause serious diseases from bloodstream infections to gonorrhoea High levels of resistance found in all regions of the world Significant gaps exist in tracking of antibiotic resistance Over the last 30 years, no major new types of antibiotics have been developed Penicillin Cephalosporin Carbapenem Fluoroquinolones Discovery void What does this mean? Without urgent action we are heading for a post-antibiotic era, in which common infections and minor injuries can once again kill What you can do Use antibiotics only when prescribed by a health professional How can infections be prevented in the first place to reduce the need for antibiotics? Better hygiene Complete the full prescription, even if you feel better Access to clean water and sanitation Infection control in healthcare facilities Vaccination Never share antibiotics with others or use leftover prescriptions More information at WHO report 2014
16 with a focus on antibiotic resistance, reveals that it is no longer a prediction for the future. Antibiotic resistance - when bacteria change and antibiotics fail - is happening right now, across the world The report is the most comprehensive picture to Looking at 7 common bacteria that cause serious High levels of resistance found in all Significant gaps exist in tracking of date, with data provided by diseases from bloodstream regions of the world antibiotic resistance 114 countries infections to gonorrhoea Over the last 30 years, no major new types of antibiotics have been developed Discovery void Penicillin Cephalosporin Carbapenem Fluoroquinolones What does this mean? Without urgent action we are heading for a post-antibiotic era, in which common infections and minor injuries can once again kill How can infections be prevented in the first place to reduce the need for antibiotics? Better Access to Infection control Vaccination hygiene clean water in healthcare and sanitation facilities What you can do Use antibiotics only when prescribed Complete the full prescription, Never share antibiotics with others
17 AMR, a global problem
18 AMR, a global problem
19 Diagnostic dilemma, therapeutic dilemma
20 Major geographic variations Whitcher et al., Int Ophthalmol Clin 2002
21 1. Introduction 2. Problem
22 Problem Treatment success depends on time/access to vision care specialists type of treatment funding compliance
23 Scenario 1 + AB +
24 Scenario 2 24h 72h CDVA 20/200
25 Zurich, Switzerland: 2004 IROC (Seiler, Mrochen, Hafezi, Iseli) ETH Swiss Federal Institute of Technology
26 Cross-Linking effects 32 Steric hindrance 3 DNA/RNA intercalation 4 Oxidative stress
27 UV-A + riboflavin = disinfectant Goodrich et al, 2000, Vox Sang Reddy et al, 2008, Transfusion Med Rev Heaselgrave et al., Appl Environ Microbiol, 2010
28 2008. Switzerland. Proof of principle. 2. First Results Post-LASIK keratitis Ten days after PACK-CXL Iseli et al, 2008, Cornea
29 PACK-CXL Hafezi et al, Journal of Refractive Surgery, Need gap: AMR 3. Need gap: Corneal infection 4. Alternative: PACK- Cross-Linking Kills both bacteria and fungi Reduce diagnostic and therapeutic dilemma Alternative to antibiotics
30 Laboratory Staph aureus growth inhibition by 97% in 30 minutes (Dresden keratoconus protocol) 2. First Results Schrier et al., IOVS,2008 Martins et al., IOVS, 2008
31 Veterinary ophthalmology. 2. First Results 1 dy 13 dys 3 mo Pot and Hafezi, Vet Ophthalmol, 2013 Mortensen et al., Vet Ophthalmol, 2013
32 2011 Phase 2 Clinical Trial No antibiotics 2. First Results Before PACK-CXL Two weeks after PACK-CXL Makdoumi et al., Curr Eye Res, 2011
33 Kill bacteria and fungi simultaneously BACTERIA Up to 98% in vitro With fluence currently used in clinical setting 2. Results 3. Optimize FUNGI 60-70% in vitro With high fluence currently used in clinical setting (7.2 J/cm 2 ) MSSA MRSA P. aeruginosa S. epidermidis C. albicans Fusarium 5.4 J/cm 2 ( ) ( ) 98% 99% 98% 97% 60-70% 60-70% Schrier et al., IOVS,2008 Martins et al., IOVS, 2008 Richoz et al., JRS, 2014 Richoz et al., unpublished data
34 Future treatment needs Optimize 2. Results Accelerate 3. Optimize Access to all
35 Simplify 2. Results 3. Optimize
36 : Early ulcers 2. Results JRS, Optimize Prospective clinical study 40 eyes. All stages of ulcer, 0-12 mm Bacterial, fungal, mixed Overall: 15% required additional treatment Early ulcers alone: none required additional treatment
37 : Early ulcers 2. Results 3. Optimize
38 : Advanced ulcers 2. Results 3. Optimize Ophthalmology, 2014 Prospective randomised clinical study 40 patients with therapy-resistant end-stage ulcer Bacterial, fungal, mixed Arm 1: Medication only, 21 eyes Arm 2: Medication plus CXL, 19 eyes Healing time comparable
39 : Advanced ulcers 2. Results 3. Optimize Ophthalmology, 2014
40 Treat Early Infiltrate / Early ulcer? Advanced ulcer? 2. Results 3. Optimize Price et al., JRS, 2012 Said et al., Ophthalmology, 2014
41 Accelerate 2. Results 3. Optimize For keratoconus? No Hammer et al, IOVS, 2014
42 Accelerate: bactericidal effect 2. First Results 3. Optimize 150 seconds, 98% killing Richoz et al, JRS, 2014
43 Phase 2 trial: accelerated PACK-CXL mw/cm 2 2. Results 3. Optimize Arm 1: antibiotics alone (n=28) Arm 2: antibiotics & CXL (n=32) Difference in healing 12 vs 7 days (p=0.001) Knyazer et al., in preparation
44 Phase 2 trial: accelerated PACK-CXL mw/cm 2 2. Results 3. Optimize Arm 1: antibiotics alone (n=28) Arm 2: antibiotics & CXL (n=32) Difference in healing 12 vs 7 days (p=0.001) Knyazer et al., in preparation
45 Swiss PACK-CXL RCT Phase 3 prospective RCT Non-inferiority study Infiltrates and small ulcers < 4 mm, < 350 µm depth 2. First Results 3. Optimize 4. Clinical data 13 sites 10 countries
46 Introduction at ESCRS 2016 Copenhagen 2. First Results 3. Optimize 4. Clinical data 5. CXL at the slit lamp C-Eye device
47 Introduction at ESCRS 2016 Copenhagen 2. First Results 3. Optimize 4. Clinical data 5. CXL at the slit lamp C-Eye device
48 C-Eye device Sterile tip Intensities delivered 2. First Results 3 mw/cm 2 9 mw/cm 2 18 mw/cm 2 30 mw/cm 2 Keratoconus Corneal Ulcer 3. Optimize 4. Clinical data 5. CXL at the slit lamp Beam optimization Safety mechanism
49 C-Eye Device 1 2. First Results 3. Optimize 2 4. Clinical data 5. CXL at the slit lamp 3 PACK-CXL EMAGine s product line offers a one-time treatment using basic equipment and infrastructure of any vision care specialist.* The use of UV light and a proprietary chromophore solution would be effective in killing all harmful pathogens in one treatment, including mixed infections. * Prophylatic anti-microbials can be administered after treatment.
50 Benefits Current PACK-CXL + 2. First Results 3. Optimize ( ) 4. Clinical data 5. CXL at the slit lamp Compliance-independent approach Diagnostic-independent approach
51 Why do PACK-CXL, antibiotics are cheap In the future: antimicrobial resistance will increase 2. First Results PACK-CXL does not only kill, but increases resistance to digestion = lesser scar 3. Optimize 4. Clinical data 5. CXL at the slit lamp Many areas of the world: doctor s costs are limiting PACK-CXL independent of diagnostic look and experience in infection assessment Less compliance issues
52
53 Zurich Mövenpick Hotel Nov 30 - Dec 2,
PACK-CXL. for infectious keratitis. Farhad Hafezi, MD PhD. Professor of Ophthalmology Keck School of Medicine USC Los Angeles, USA
PACK-CXL for infectious keratitis Farhad Hafezi, MD PhD Professor of Ophthalmology University of Geneva Geneva, Switzerland Medical Director ELZA Institute Zurich, Switzerland Research Group Leader Lab.
More informationHorses treated by PACK-CXL
Horses treated by PACK-CXL Anna Hellander Edman, Jes Mortensen & Björn Ekesten Zurich December 2014 Jes Mortensen,MD Sweden 0 Autumn 2009 the first keratitis in a horse was treated by PACK-CXL by our group
More informationWHO s first global report on antibiotic resistance reveals serious, worldwide threat to public health
New WHO report provides the most comprehensive picture of antibiotic resistance to date, with data from 114 countries 30 APRIL 2014 GENEVA - A new report by WHO its first to look at antimicrobial resistance,
More informationClinical Features, Antibiotic Susceptibility Profile, and Outcomes of Infectious Keratitis Caused by Stenotrophomonas maltophilia
Clinical Features, Antibiotic Susceptibility Profile, and Outcomes of Infectious Keratitis Caused by Stenotrophomonas maltophilia Sotiria Palioura, MD, MSc, PhD Cornea & External Disease Specialist Athens
More informationStudy of Bacteriological Profile of Corneal Ulcers in Patients Attending VIMS, Ballari, India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 7 (2016) pp. 200-205 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.507.020
More informationHow is Ireland performing on antibiotic prescribing?
European Antibiotic Awareness Campaign 2016 November Webinar Series on Antibiotic Prescribing How is Ireland performing on antibiotic prescribing? Dr Rob Cunney National Clinical Lead HCAI AMR Clinical
More informationAntibiotic resistance is one of the biggest threats to global health, food security, and development today.
Antibiotic resistance Fact sheet Updated November 2017 Key facts Antibiotic resistance is one of the biggest threats to global health, food security, and development today. Antibiotic resistance can affect
More informationThe South African AMR strategy. 3 rd Annual Regulatory Workshop Gavin Steel Sector wide Procurement National Department of Health; South Africa
The South African AMR strategy 3 rd Annual Regulatory Workshop Gavin Steel Sector wide Procurement National Department of Health; South Africa Background to AMR 2 What is Antimicrobial stewardship and
More informationNew Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs
New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks
More informationImagine. Multi-Drug Resistant Superbugs- What s the Big Deal? A World. Without Antibiotics. Where Simple Infections can be Life Threatening
Multi-Drug Resistant Superbugs- What s the Big Deal? Toni Biasi, RN MSN MPH CIC Infection Prevention Indiana University Health Imagine A World Without Antibiotics A World Where Simple Infections can be
More informationRole of Moxifloxacin in Bacterial Keratitis
Original Article Role of Moxifloxacin in Bacterial Keratitis Aamna Jabran, Aurengzeb Sheikh, Syed Ali Haider, Zia-ud-din Shaikh Pak J Ophthalmol 29, Vol. 25 No. 2.................................................................................
More informationReview Article New Treatments for Bacterial Keratitis
Hindawi Publishing Corporation Journal of Ophthalmology Volume 2012, Article ID 831502, 7 pages doi:10.1155/2012/831502 Review Article New Treatments for Bacterial Keratitis RaymondL.M.Wong, 1 R. A. Gangwani,
More informationBurden of disease of antibiotic resistance The example of MRSA. Eva Melander Clinical Microbiology, Lund University Hospital
Burden of disease of antibiotic resistance The example of MRSA Eva Melander Clinical Microbiology, Lund University Hospital Discovery of antibiotics Enormous medical gains Significantly reduced morbidity
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationWORLD ANTIBIOTIC AWARENESS WEEK
# AntibioticResistance WORLD ANTIBIOTIC AWARENESS WEEK 14-20 NOVEMBER 2016 2016 CAMPAIGN TOOLKIT TABLE OF CONTENTS Why we need a global campagin... Campagin objectives... Key messages... Calls to action
More informationHealthcare Facilities and Healthcare Professionals. Public
Document Title: DOH Guidelines for Antimicrobial Stewardship Programs Document Ref. Number: DOH/ASP/GL/1.0 Version: 1.0 Approval Date: 13/12/2017 Effective Date: 14/12/2017 Document Owner: Applies to:
More informationCollecting and Interpreting Stewardship Data: Breakout Session
Collecting and Interpreting Stewardship Data: Breakout Session Michael S. Calderwood, MD, MPH Regional Hospital Epidemiologist, Dartmouth-Hitchcock Medical Center March 20, 2019 None Disclosures Outline
More informationVaccination as a potential strategy to combat Antimicrobial Resistance in the elderly
Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly Wilbur Chen, MD, MS 22-23 March 2017 WHO meeting on Immunization of the Elderly The Problem Increasing consumption
More informationImpact of Antimicrobial Resistance on Human Health. Robert Cunney HSE HCAI/AMR Programme and Temple Street Children s University Hospital
Impact of Antimicrobial Resistance on Human Health Robert Cunney HSE HCAI/AMR Programme and Temple Street Children s University Hospital AMR in Foodchain Conference, UCD, Dec 2014 Sir Patrick Dun s Hospital
More informationFor Alberta broiler producers, the biggest impacts will be:
Changes to Health Canada s Prescription Drug List: Getting Ready for Changes in Veterinary Oversight Requirements On December 1, 2018 prescription requirements for medically important antimicrobials come
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationMICRO-ORGANISMS by COMPANY PROFILE
MICRO-ORGANISMS by COMPANY PROFILE 2017 1 SAPROPHYTES AND PATHOGENES SAPROPHYTES Not dangerous PATHOGENES Inducing diseases Have to be eradicated WHERE ARE THERE? EVERYWHERE COMPANY PROFILE 2017 3 MICROORGANISMS
More informationHorizontal vs Vertical Infection Control Strategies
GUIDE TO INFECTION CONTROL IN THE HOSPITAL Chapter 14 Horizontal vs Vertical Infection Control Strategies Author Salma Abbas, MBBS Michael Stevens, MD, MPH Chapter Editor Shaheen Mehtar, MBBS. FRC Path,
More informationAntibiotic Resistance
Preparing for the Battle Antibiotic Resistance Joy Jiao Systems Biology, Harvard University World Health Organization Global Report on Antibiotic Resistance, 01: resistance to common bacteria has reached
More informationAntibiotic resistance: the rise of the superbugs
Antibiotic resistance: the rise of the superbugs Allen Cheng Associate Professor of Infectious Diseases Epidemiology, Alfred Health; Monash University About me Specialist in infectious diseases Head, Infection
More informationEvaluation of EU strategy to combat AMR
Evaluation of EU strategy to combat AMR Advisory Group of the Food Chain 30 April 2015 Martial Plantady Legislative officer DDG2.G4: Food, Alert Systems & Training DG Health and Food Safety Antimicrobial
More informationRise of the Superbugs: the end of antibiotics? Peter Lambert Life and Health Sciences Aston University
Rise of the Superbugs: the end of antibiotics? Peter Lambert Life and Health Sciences Aston University Willard Wigan Microbiologists grow bacteria on plates Each colony is formed from a single cell Colonies
More informationOverview of Infection Control and Prevention
Overview of Infection Control and Prevention Review of the Cesarean-section Antibiotic Prophylaxis Program in Jordan and Workshop on Rational Medicine Use and Infection Control Terry Green and Salah Gammouh
More informationCombating Antimicrobial Resistance: The Way Forward
Combating Antimicrobial Resistance: The Way Forward James M. Hughes, MD Professor of Medicine and Public Health Emory University Atlanta, GA NIAA Antibiotic Symposium November 14, 2014 Disclosure No conflicts
More informationTyphoid fever - priorities for research and development of new treatments
Typhoid fever - priorities for research and development of new treatments Isabela Ribeiro, Manica Balasegaram, Christopher Parry October 2017 Enteric infections Enteric infections vary in symptoms and
More informationEVIDENCE BASED MEDICINE: ANTIBIOTIC RESISTANCE IN THE ELDERLY CHETHANA KAMATH GERIATRIC MEDICINE WEEK
EVIDENCE BASED MEDICINE: ANTIBIOTIC RESISTANCE IN THE ELDERLY CHETHANA KAMATH GERIATRIC MEDICINE WEEK EPIDEMIOLOGY AND BACKGROUND Every year, more than 2 million people in the United States acquire antibiotic-resistant
More informationWhat s happening across the UK with antimicrobial prescribing quality indicators?
What s happening across the UK with antimicrobial prescribing quality indicators? Dr Jacqueline Sneddon, MRPharmS Project Lead, Scottish Antimicrobial Prescribing Group Antimicrobial Management Team Network
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More information2016/LSIF/FOR/003 Strengthening Surveillance and Laboratory Capacity to Fight Healthcare Associated Infections Antimicrobial Resistance
2016/LSIF/FOR/003 Strengthening Surveillance and Laboratory Capacity to Fight Healthcare Associated Infections Antimicrobial Resistance Submitted by: Viet Nam Policy Forum on Strengthening Surveillance
More informationGlobal Status of Antimicrobial Resistance with a Focus on Nepal
Global Status of Antimicrobial Resistance with a Focus on Nepal John Ferguson, John Hunter Hospital, University of Newcastle, NSW, Australia Infectious Diseases Physician and Medical Microbiologist SIMON
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationS aureus infections: outpatient treatment. Dirk Vogelaers Dept of Infectious Diseases University Hospital Gent Belgium
S aureus infections: outpatient treatment Dirk Vogelaers Dept of Infectious Diseases University Hospital Gent Belgium Intern Med J. 2005 Feb;36(2):142-3 Intern Med J. 2005 Feb;36(2):142-3 Treatment of
More informationAntimicrobial stewardship in companion animals: Welcome to a whole new era
Antimicrobial stewardship in companion animals: Welcome to a whole new era John F. Prescott, University Professor Emeritus, Department of Pathobiology, University of Guelph, Guelph, Ontario NG 2W1 prescott@uoguelph.ca
More informationAntibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco
Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance
More informationTREAT Steward. Antimicrobial Stewardship software with personalized decision support
TREAT Steward TM Antimicrobial Stewardship software with personalized decision support ANTIMICROBIAL STEWARDSHIP - Interdisciplinary actions to improve patient care Quality Assurance The aim of antimicrobial
More informationAntibiotic Stewardship in the LTC Setting
Antibiotic Stewardship in the LTC Setting Joe Litsey, Director of Consulting Services Pharm.D., Board Certified Geriatric Pharmacist Thrifty White Pharmacy Objectives Describe the Antibiotic Stewardship
More informationAntimicrobial Resistance and Papua New Guinea WHY is it important? HOW has the problem arisen? WHAT can we do?
Antimicrobial Resistance and Papua New Guinea WHY is it important? HOW has the problem arisen? WHAT can we do? John Ferguson, John Hunter Hospital, University of Newcastle, NSW, Australia Infectious Diseases
More informationAntimicrobial Stewardship. Where are we now and where do we need to go?
Safe Patient Care Bugs and Drugs The ongoing challenge of MDROs and AMR 2017 @SPC2016Cork Antimicrobial Stewardship. Where are we now and where do we need to go? Frank O Riordan Antimicrobial pharmacist,
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More informationAntibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine. Mike Apley Kansas State University
Antibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine Mike Apley Kansas State University Changes in Food Animal Antibiotic Use How the uses of antibiotics in
More informationANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS
ANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS PHM025D March 2016 Neha Maliwal Project Analyst ISBN: 1-62296-252-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationPathogens and Antibiotic Sensitivities in Post- Phacoemulsification Endophthalmitis, Kaiser Permanente, California,
Pathogens and Antibiotic Sensitivities in Post- Phacoemulsification Endophthalmitis, Kaiser Permanente, California, 2007-2012 Geraldine R. Slean, MD, MS 1 ; Neal H. Shorstein, MD 2 ; Liyan Liu, MD, MS
More informationStratégie et action européennes
Résistance aux antibiotiques : une impasse thérapeutique? Implications nationales et internationales Stratégie et action européennes Dominique L. Monnet, Senior Expert and Head of Disease Programme Antimicrobial
More informationrunning head: SUPERBUGS Humphreys 1
running head: SUPERBUGS Humphreys 1 Superbugs GCH 360 Term Paper Assignment Kelly Humphreys April 30, 2014 SUPERBUGS Humphreys 2 Introduction The World Health Organization (WHO) recognizes antibiotic resistance
More informationDisclosure. Update on management of fungal keratitis. Acknowledgments. World Blindness 1993
Update on management of fungal keratitis Tom Lietman, MD F I Proctor Foundation Department of Ophthalmology University of California San Francisco Disclosure Voriconazole donated by Pfizer Natamycin and
More informationThe importance of infection control in the era of multi drug resistance
Dr. Kumar Consultant Infectious Diseases Physician Hospital Sungai buloh The importance of infection control in the era of multi drug resistance Nosocomial infections In Australian acute hospitals 200,000
More informationREPORT ON THE ANTIMICROBIAL RESISTANCE (AMR) SUMMIT
1 REPORT ON THE ANTIMICROBIAL RESISTANCE (AMR) SUMMIT The Department of Health organised a summit on Antimicrobial Resistance (AMR) the purpose of which was to bring together all stakeholders involved
More informationChallenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S.
Challenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S. Overview of benchmarking Antibiotic Use Scott Fridkin, MD, Senior Advisor for Antimicrobial
More informationHealthcare-associated infections surveillance report
Healthcare-associated infections surveillance report Methicillin-resistant Staphylococcus aureus (MRSA) Update, Q3 of 2017/18 Summary Table Q3 2017/18 Previous quarter (Q2 2017/18) Same quarter of previous
More informationQuality indicators and outcomes in the devolved nations Scotland
Quality indicators and outcomes in the devolved nations Scotland Dr Jacqueline Sneddon, MRPharmS Project Lead, Scottish Antimicrobial Prescribing Group Federation of Infection Societies Conference Birmingham,
More information11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose
Antimicrobial Stewardship Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University
More information3/1/2016. Antibiotics --When Less is More. Most Urgent Threats. Serious Threats
Antibiotics --When Less is More Ralph Gonzales, MD, MSPH Associate Dean, Clinical Innovation School of Medicine VP, Clinical Innovation, UCSF Health Most Urgent Threats Serious Threats Multidrug-Resistant
More informationCorneal collagen cross-linking (CXL) for the treatment of melting keratitis in cats and dogs: a pilot study
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse CH-0 Zurich www.zora.uzh.ch Year: Corneal collagen cross-linking (CXL) for the treatment of melting keratitis in cats
More informationDR. BASHIRU BOI KIKIMOTO
OVERVIEW OF ANTIMICROBIAL RESISTANCE AND ANTIMICROBIAL USE IN GHANA PRESENTED BY : DR. BASHIRU BOI KIKIMOTO DVM. PhD VETERINARY PUBLIC HEALTH HEAD - PUBLIC HEALTH UNIT & FOOD SAFETY UNIT VENUE: SWATZILAND
More informationIFMSA Policy Proposal Antimicrobial Resistance
IFMSA Policy Proposal Antimicrobial Resistance Proposed by Team of Officials Presented to the IFMSA General Assembly March Meeting 2017 in Arusha, Tanzania Policy Statement Introduction Antimicrobial resistance
More informationAntimicrobial Copper Touch Surfaces: A new tool for Infection Control and Prevention
Antimicrobial Copper Touch Surfaces: A new tool for Infection Control and Prevention Wilton Moran Project Engineer Copper Development Association The Science Behind the Technology Digital Summit Infection
More informationWhy should we care about multi-resistant bacteria? Clinical impact and
Why should we care about multi-resistant bacteria? Clinical impact and public health implications Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland and Ebola (in 2014/2015) Increased
More informationIntroduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018
Introduction to Chemotherapeutic Agents Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Antimicrobial Agents Substances that kill bacteria without harming the host.
More informationMDRO s, Stewardship and Beyond. Linda R. Greene RN, MPS, CIC
MDRO s, Stewardship and Beyond Linda R. Greene RN, MPS, CIC linda_greene@urmc.rochester.edu Evolving Threat of Antimicrobial Resistance Why are MDROs important? Limited treatment options Associated with:
More informationDr Marc Sprenger Director Antimicrobial Resistance Secretariat Global action plan on antimicrobial resistance
Global Action Plan on Antimicrobial Resistance Dr Marc Sprenger Director Antimicrobial Resistance Secretariat When are we entering the post-antibiotic era? For some diseases we have already entered! Fatal
More informationAntibiotic Stewardship in the Hospital Setting
Antibiotic Stewardship in the Hospital Setting G. Evans, MD FRCPC Medical Director, Infection Prevention & Control Kingston General Hospital & Hotel Dieu Hospital EOPIC September 26, 2012 Stewardship stew-ard-ship
More informationWill 10 Million People Die a Year due to Antimicrobial Resistance by 2050? Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland
Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland Thanks for material provided by Marlieke de Kraker & Andrew
More informationGet Smart For Healthcare
Get Smart For Healthcare Know When Antibiotics Work Marry Bardin, Quality Improvement Advisor June 9, 2015 Why We Need to Improve In-patient Antibiotic Use Antibiotics are misused in hospitals Antibiotic
More informationAntibiotic courses and antibiotic conservation, getting the balance right
Antibiotic courses and antibiotic conservation, getting the balance right Prof Martin Llewelyn Brighton and Sussex Medical School Brighton and Sussex University Hospitals NHS Trust The King's Fund: Ideas
More informationREVIEW OF OPHTHALMOLOGY SECTION OF WHO MODEL LIST OF ESSENTIAL MEDICINES. Sight Savers International and The Vision 2020 Technology Group
REVIEW OF OPHTHALMOLOGY SECTION OF WHO MODEL LIST OF ESSENTIAL MEDICINES Anti infective agent Medicine suggested for inclusion Ciprofloxacin: 0.3 % eye drops Application submitted by Sight Savers International
More informationOptimizing Antimicrobial Stewardship Activities Based on Institutional Resources
Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources Andrew Hunter, PharmD, BCPS Infectious Diseases Clinical Pharmacy Specialist Michael E. DeBakey VA Medical Center Andrew.hunter@va.gov
More informationAntibiotic resistance: how did we get here and what can we do? Peter Lambert LHS
Antibiotic resistance: how did we get here and what can we do? Peter Lambert LHS How do we diagnose and treat infection? Organisms are cultured and identified Microscopy gives a clue to identity Staphylococcus
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationAntibiotic Review Kit - Hospital
The International Convention Centre (ICC), Birmingham 11 12 September 2017 Antibiotic Review Kit - Hospital (ARK-hospital) Elizabeth Cross Brighton and Sussex University Hospitals NHS Trust Brighton and
More informationchoice The Rilexine Palatable Tablets First generation cephalosporin for skin infections Now registered for ONCE daily administration*
Virbac Dermatology Palatable Tablets The choice First generation cephalosporin for skin infections Now registered for ONCE daily administration* are only available under Veterinary Authorisation. www.virbac.co.nz
More information8/17/2016 ABOUT US REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM
Mary Moore, MS CIC MT (ASCP) Infection Prevention Coordinator Great River Medical Center, West Burlington REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM ABOUT
More informationSurveillance of AMR in PHE: a multidisciplinary,
Surveillance of AMR in PHE: a multidisciplinary, integrated approach Professor Neil Woodford Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit Crown copyright International
More informationThese life-saving drugs have been a boon to medical care and benefited hundreds of million patients around the globe.
SINCE Sir Alexander Fleming, a Scottish biologist, pharmacologist and botanist (a 1945 Nobel laureate), first discovered penicillin in 1923, hundreds of more potent wider spectrum antibiotics have been
More informationEnglish Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR)
English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Berit Muller-Pebody HCAI & AMR Department, Centre for Infectious Disease Surveillance and Control Chief Medical Officer
More informationClostridium Difficile Infection (CDI) Alistair McGregor Hobart Pathology Royal Hobart Hospital TIPCU
Clostridium Difficile Infection (CDI) Alistair McGregor Hobart Pathology Royal Hobart Hospital TIPCU Disclosures I am not Tom Riley The Fidaxomicin guys brought me dinner once Outline ASID/AICA position
More informationBacterial Keratitis Should optometrists treat in the community?
Case Record 13 Bacterial Keratitis Should optometrists treat in the community? December 2008 Dr Peter Frampton DOptom MSc FCOptom BAppSc(Optom)(AUS) DipTp(AS) DipTp(SP) DipTp(IP) Introduction Can Optometrists
More informationAntibacterial Agents & Conditions. Stijn van der Veen
Antibacterial Agents & Conditions Stijn van der Veen Antibacterial agents & conditions Antibacterial agents Disinfectants: Non-selective antimicrobial substances that kill a wide range of bacteria. Only
More informationThe challenge of growing resistance
EXECUTIVE SUMMARY Around 2.4 million people could die in Europe, North America and Australia between 2015-2050 due to superbug infections unless more is done to stem antibiotic resistance. However, three
More information03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline
Infection Prevention and Control A Foundation Course 2014 What is healthcare-associated infection (HCAI), antimicrobial resistance (AMR) and multi-drug resistant organisms (MDROs)? Why we should be worried?
More informationAntibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship
Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship J. Hudson Garrett Jr., PhD, MSN, MPH, FNP-BC, PLNC, CDONA, IP-BC, GDCN, CDP, CADDCT, CALN, VA-BC, AS-BC,
More informationDevelopment and improvement of diagnostics to improve use of antibiotics and alternatives to antibiotics
Priority Topic B Diagnostics Development and improvement of diagnostics to improve use of antibiotics and alternatives to antibiotics The overarching goal of this priority topic is to stimulate the design,
More informationRedefining Infection Management. Proven Clinical Outcomes
Proven Clinical Outcomes Proof of Bacteria-Binding1 In the first 30 seconds, 1 square centimeter of Cutimed Sorbact binds wound bacteria - after 2 hours, the amount of bacteria bound are more than would
More informationAntimicrobial Resistance and One Health: Research Needs
Antimicrobial Resistance and One Health: Research Needs Amelia Woolums, DVM PhD DACVIM DACVM College of Veterinary Medicine, Mississippi State University amelia.woolums@msstate.edu Why do we use antimicrobials?
More informationAntibiotic treatment in the ICU 1. ICU Fellowship Training Radboudumc
Antibiotic treatment in the ICU 1 ICU Fellowship Training Radboudumc Main issues Delayed identification of microorganisms Impact of critical illness on Pk/Pd High prevalence of antibiotic resistant strains
More informationResponsible use of antibiotics
Responsible use of antibiotics Uga Dumpis MD, PhD Department of Infectious Diseases and Infection Control Pauls Stradiņs Clinical University Hospital Challenges in the hospitals Antibiotics are still effective
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationUSA ACTION PLAN FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA
FMM/RAS/298: Strengthening capacities, policies and national action plans on prudent and responsible use of antimicrobials in fisheries Final Workshop in cooperation with AVA Singapore and INFOFISH 12-14
More informationANTIMICROBIAL STEWARDSHIP
ANTIMICROBIAL STEWARDSHIP Australian Pig Veterinarians Annual Conference 11-12 September, 2017 Stephen Page Advanced Veterinary Therapeutics swp@advet.com.au OUTLINE Importance of AMR Antimicrobial use
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationAntimicrobial Resistance Update for Community Health Services
Antimicrobial Resistance Update for Community Health Services Elizabeth Beech Healthcare Acquired Infection and Antimicrobial Resistance Project Lead NHS England October 2015 elizabeth.beech@nhs.net Superbugs
More informationSelective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016
Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that
More informationDr. P. P. Doke. M.D., D.N.B., Ph.D., FIPHA. Professor, Department of Community Medicine, Bharati Vidyapeeth Medical College, Pune
Dr. P. P. Doke M.D., D.N.B., Ph.D., FIPHA Professor, Department of Community Medicine, Bharati Vidyapeeth Medical College, Pune 1 Anti microbial resistance is now a global geometrically increasing threat
More informationWhy Don t These Drugs Work Anymore? Biosciences in the 21 st Century Dr. Amber Rice October 28, 2013
Why Don t These Drugs Work Anymore? Biosciences in the 21 st Century Dr. Amber Rice October 28, 2013 Outline Drug resistance: a case study Evolution: the basics How does resistance evolve? Examples of
More information